HK Stock Market Move | Brain-machine interface concept stocks lead the decline, institutions say that in the short term, the commercialization of brain-machine interfaces will focus more on non-invasive methods.

date
14:53 13/01/2026
avatar
GMT Eight
Concept stocks of brain-machine interfaces lead the decline, as of the time of writing, Nanjing Panda Electronics Co., Ltd. (00553) fell by 8.29% to HKD 5.53; Blue Think Technology Co., Ltd. (06613) fell by 5.74% to HKD 28.26; BrainGo Aurora-B (06681) fell by 5.7% to HKD 7.11; MicroPort NeuroTech (02172) fell by 2.23% to HKD 13.15.
Concept stocks of brain-computer interfaces led the decline. As of the time of writing, NANJING PANDA (00553) fell by 8.29% to 5.53 Hong Kong dollars; Lens Technology (06613) fell by 5.74% to 28.26 Hong Kong dollars; BRAINAURORA-B (06681) fell by 5.7% to 7.11 Hong Kong dollars; MICROPORT NEURO (02172) fell by 2.23% to 13.15 Hong Kong dollars. In terms of news, Nanjing Panda Electronics previously announced in a notice on abnormal stock price fluctuations that the company's main business focuses on smart transportation and safe cities, industrial Internet and smart manufacturing, and green service-oriented electronic manufacturing. As of now, the company has no mature products related to brain-computer interfaces and has not generated any related sales revenue, so the concept will not have a substantial impact on the company's current production and operation. Wanlian Securities pointed out that in the short term, the commercialization of brain-computer interfaces is more focused on non-invasive methods, while in the medium to long term, the core lies in upstream technologies such as (semi-) invasive/invasive "flexible electrodes + high-throughput low-power chips", multicenter clinical trials, compliance standards, and other comprehensive system capabilities. Industry policy support, medical insurance payments, breakthroughs in registered clinical milestones, core technological breakthroughs, and domestic substitution are all future catalysts for industry development. Invasive methods focus on R&D teams, clinical resources, financing environment, etc.; non-invasive methods focus on branding, channels, and cost control.